EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
Status:
Recruiting
Trial end date:
2021-11-25
Target enrollment:
Participant gender:
Summary
The aim of this trial is to identify the maximum tolerated dose (MTD)/recommended phase II
dose (RP2D), to define pharmacokinetic (PK) parameters and the preliminary efficacy of a
continuous treatment with EGF816 and trametinib in locally advanced or metastatic (stage IIIB
or IV) lung cancer patients with activating mutations in the epithelial growth factor
receptor (EGFR).